Follow The Filings

ARQT Arcutis Biotherapeutics Inc.

Health Care, filed as ARCUTIS BIOTHERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.1%
  • $33M
  • 1 add 1 exit

In 2026 Q2 Ron Baron added to Arcutis Biotherapeutics, while Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Ron Baron, Bamco Inc. (Baron Capital)). Not free-float ownership.

  1. Ron Baron Add 0.05%

Who owns ARQT

Sorted by value, long equity only, as of 2026 Q2.

History
Ron Baron, Bamco Inc. (Baron Capital) 0.05% Add +16.9% 1,253,120 $33M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 26,000 $613K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ARQT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARQT insider trades
  • None no insider bought on the open market
  • $3.3M sold by 5 insiders outside a trading plan
  • $8.6M sold by 7 insiders under 10b5-1 plans
  1. Howard G. Welgus Director
    Planned sale
    $127K 4,728 shares at $26.93 12% of stake
    Traded Oct 15 Filed Oct 19
    ↗
  2. Masaru Matsuda See Remarks
    Planned sale
    $92K 3,674 shares at $25.00 3.2% of stake
    Traded Sep 16 Filed Sep 18
    ↗
  3. Howard G. Welgus Director
    Planned sale
    $114K 4,730 shares at $24.18 12% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  4. Masaru Matsuda See Remarks
    Planned sale
    $250K 9,989 shares at $25.03 7.9% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  5. Terrie Curran Director
    Sale
    $956K 38,200 shares at $25.03 62% of stake
    Traded Aug 27 Filed Aug 28
    ↗
  6. Terrie Curran Director
    Sale
    $28K 1,072 shares at $26.04 4.4% of stake
    Traded Aug 20 Filed Aug 24
    ↗
  7. Howard G. Welgus Director
    Planned sale
    $124K 4,730 shares at $26.18 12% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  8. Patrick Burnett See Remarks
    Sale
    $395K 15,000 shares at $26.33 11% of stake
    Traded Aug 11–12 Filed Aug 13
    ↗
  9. Howard G. Welgus Director
    Planned sale
    $127K 4,730 shares at $26.91 11% of stake
    Traded Jul 15 Filed Jul 17
    ↗
  10. Sue-Jean Lin Director
    Planned sale
    $121K 4,946 shares at $24.38 15% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  11. Howard G. Welgus Director
    Planned sale
    $116K 4,731 shares at $24.58 11% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  12. Masaru Matsuda See Remarks
    Planned sale
    $172K 7,372 shares at $23.27 5.5% of stake
    Traded May 4 Filed May 6
    ↗
  13. Howard G. Welgus Director
    Planned sale
    $164K 7,144 shares at $22.99 18% of stake
    Traded May 1 Filed May 5
    ↗
  14. Howard G. Welgus Director
    Planned sale
    $239K 10,000 shares at $23.88 20% of stake
    Traded Apr 1 Filed Apr 3
    ↗
  15. Keith R Leonard Director
    Planned sale
    $997K 39,272 shares at $25.39 64% of stake
    Traded Mar 2 Filed Mar 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 36 sales to cover taxes, 29 option exercises, 16 stock grants, and 1 gift.

Congress

1 member of Congress traded ARQT in the last three years: 2 buys and 1 sale. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K May 29 filed Jun 8
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Dec 11, 2025 filed Jan 12

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.07,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $59.61M $166.54M $372.07M
Gross profit * $54.62M $147.41M $335.38M
Gross margin * 91.6% 88.5% 90.1%
Net income -$262.14M -$140.04M -$16.14M
Net margin * -439.8% -84.1% -4.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $330.43M $335.82M $411.23M
Total non-current assets * $10.93M $13.07M $21.74M
Total assets $341.36M $348.89M $432.97M
Total current liabilities $46.67M $81.01M $129.84M
Total non-current liabilities * $206.03M $110.34M $113.66M
Total equity $88.67M $157.54M $189.48M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$247.06M -$112.16M -$5.62M
Cash from investing $180.23M $28.82M -$30.25M
Cash from financing $101.32M $66.2M $6.97M
Net change in cash $34.45M -$17.37M -$28.74M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.